Skip to main content

In Brief This Week: NobleGen Biosciences; Exiqon; Waters

NEW YORK (GenomeWeb News) – NobleGen Biosciences has received a $182,000 Phase I SBIR grant from the National Human Genome Research Institute top optimize chemistry for its Optipore sequencing technology. The Concord, Mass.-based firm is developing a nanopore-based method for DNA sequencing by nanopore induced photon emission (SNIPE).

According to GenomeWeb Daily News sister publication Clinical Sequencing News, NobleGen wants to target clinical sequencing tests with its platform and is confident that it will be able to achieve a turnaround time of less than 24 hours for sequencing and assembling a human genome for "significantly less" than $2,000 in total costs, including labor and IT.

Exiqon said this week that the Roswell Park Cancer Institute in Buffalo, NY will serve as a center of excellence, offering real-time PCR services based on Exiqon's mircury LNA Universal RT microRNA PCR product line.

Waters this week said this week that the University of Minnesota's Mass Spectrometry Laboratory has joined the firm's Centers of Innovation Program. The lab is one of 13 Centers of Innovation named by Waters.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.